U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C56H87NO16
Molecular Weight 1030.2892
Optical Activity UNSPECIFIED
Defined Stereocenters 15 / 15
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TEMSIROLIMUS

SMILES

C[C@]1([H])/C(/[H])=C(\[H])/C(/[H])=C(\[H])/C(/[H])=C(\C)/[C@]([H])(C[C@]2([H])CC[C@@]([H])(C)[C@@](C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O[C@@]([H])(CC(=O)[C@]([H])(C)/C(/[H])=C(\C)/[C@]([H])([C@]([H])(C(=O)[C@]([H])(C)C1)OC)O)[C@]([H])(C)C[C@]4([H])CC[C@]([H])([C@@]([H])(C4)OC)OC(=O)C(C)(CO)CO)(O)O2)OC

InChI

InChIKey=CBPNZQVSJQDFBE-FUXHJELOSA-N
InChI=1S/C56H87NO16/c1-33-17-13-12-14-18-34(2)45(68-9)29-41-22-20-39(7)56(67,73-41)51(63)52(64)57-24-16-15-19-42(57)53(65)71-46(30-43(60)35(3)26-38(6)49(62)50(70-11)48(61)37(5)25-33)36(4)27-40-21-23-44(47(28-40)69-10)72-54(66)55(8,31-58)32-59/h12-14,17-18,26,33,35-37,39-42,44-47,49-50,58-59,62,67H,15-16,19-25,27-32H2,1-11H3/b14-12+,17-13+,34-18+,38-26+/t33-,35-,36-,37-,39-,40+,41+,42+,44-,45+,46+,47-,49-,50+,56-/m1/s1

HIDE SMILES / InChI

Molecular Formula C56H87NO16
Molecular Weight 1030.2892
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 15 / 15
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022088s000_PRNTLBL.pdf

Temsirolimus is an intravenous drug for the treatment of renal cell carcinoma (RCC), developed by Wyeth Pharmaceuticals and approved by the FDA in late May 2007, and was also approved by the European Medicines Agency (EMEA) on November 2007. It is a derivative of sirolimus and is sold as Torisel. Temsirolimus is an inhibitor of mTOR (mammalian target of rapamycin). Temsirolimus binds to an intracellular protein (FKBP-12), and the protein-drug complex inhibits the activity of mTOR that controls cell division. Inhibition of mTOR activity resulted in a G1 growth arrest in treated tumor cells. When mTOR was inhibited, its ability to phosphorylate p70S6k and S6 ribosomal protein, which are downstream of mTOR in the PI3 kinase/AKT pathway was blocked. In in vitro studies using renal cell carcinoma cell lines, temsirolimus inhibited the activity of mTOR and resulted in reduced levels of the hypoxia-inducible factors HIF-1 and HIF-2 alpha, and the vascular endothelial growth factor.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
1.76 µM [IC50]
Target ID: CHEMBL614067
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Torisel

Approved Use

Treatment of advanced renal cell carcinoma (RCC)

Launch Date

1.18039681E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
585 ng/mL
25 mg single, intravenous
dose: 25 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
TEMSIROLIMUS blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1627 ng × h/mL
25 mg single, intravenous
dose: 25 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
TEMSIROLIMUS blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
17.3 h
25 mg single, intravenous
dose: 25 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
TEMSIROLIMUS blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
11%
25 mg single, intravenous
dose: 25 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
TEMSIROLIMUS blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
150 mg/m2 1 times / week multiple, intravenous
Dose: 150 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 150 mg/m2, 1 times / week
Sources:
unhealthy, 11 years (range: 4-21 years)
n = 7
Health Status: unhealthy
Condition: Recurrent/Refractory Solid Tumors
Age Group: 11 years (range: 4-21 years)
Sex: M+F
Population Size: 7
Sources:
DLT: Anorexia...
Dose limiting toxicities:
Anorexia (grade 3, 1 patient)
Sources:
220 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 220 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 220 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 30-63 years)
n = 9
Health Status: unhealthy
Condition: solid tumor refractory
Age Group: 54 years (range: 30-63 years)
Sex: M+F
Population Size: 9
Sources:
DLT: Stomatitis, Asthenia...
Other AEs: Mucositis, Mucositis...
Dose limiting toxicities:
Stomatitis (grade 3, 1 patient)
Asthenia (grade 3, 1 patient)
Other AEs:
Mucositis (grade 1-2, 7 patients)
Mucositis (grade 3-4, 1 patient)
Nausea (grade 1-2, 5 patients)
Thrombocytopenia (grade 1-2, 1 patient)
Diarrhea (grade 1-2, 1 patient)
Vomiting (grade 1-2, 3 patients)
Hypercholesterolemia (grade 3-4, 2 patients)
Hypertriglyceridemia (grade 3-4, 1 patient)
Peripheral edema (grade 1-2, 2 patients)
Weight loss (grade 1-2, 2 patients)
Taste perversion (grade 1-2, 2 patients)
Sources:
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Other AEs: Asthenia, Asthenia...
Other AEs:
Asthenia (all grades, 51%)
Asthenia (grade 3-4, 11%)
Edema (all grades, 35%)
Edema face (all grades, 35%)
Peripheral edema (all grades, 35%)
Edema (grade 3-4, 3%)
Edema face (grade 3-4, 3%)
Peripheral edema (grade 3-4, 3%)
Pain (all grades, 28%)
Pain (grade 3-4, 5%)
Pyrexia (all grades, 24%)
Pyrexia (grade 3-4, 1%)
Weight loss (all grades, 19%)
Weight loss (grade 3-4, 1%)
Headache (all grades, 15%)
Headache (grade 3-4, 1%)
Chest pain (all grades, 16%)
Chest pain (grade 3-4, 1%)
Chills (all grades, 8%)
Chills (grade 3-4, 1%)
Aphthous stomatitis (all grades, 41%)
Glossitis (all grades, 41%)
Mouth ulceration (all grades, 41%)
Mucositis (all grades, 41%)
Stomatitis (all grades, 41%)
Aphthous stomatitis (grade 3-4, 3%)
Glossitis (grade 3-4, 3%)
Mouth ulceration (grade 3-4, 3%)
Mucositis (grade 3-4, 3%)
Stomatitis (grade 3-4, 3%)
Anorexia (all grades, 32%)
Anorexia (grade 3-4, 3%)
Nausea (all grades, 37%)
Nausea (grade 3-4, 2%)
Diarrhea (all grades, 27%)
Diarrhea (grade 3-4, 1%)
Abdominal pain (all grades, 21%)
Abdominal pain (grade 3-4, 4%)
Constipation (all grades, 20%)
Vomiting (all grades, 19%)
Vomiting (grade 3-4, 2%)
Infection NOS (all grades, 20%)
Abscess (all grades, 20%)
Bronchitis (all grades, 20%)
Cellulitis (all grades, 20%)
Herpes simplex (all grades, 20%)
Herpes zoster (all grades, 20%)
Infection NOS (grade 3-4, 3%)
Abscess (grade 3-4, 3%)
Bronchitis (grade 3-4, 3%)
Cellulitis (grade 3-4, 3%)
Herpes simplex (grade 3-4, 3%)
Herpes zoster (grade 3-4, 3%)
Cystitis (all grades, 15%)
Dysuria (all grades, 15%)
Hematuria (all grades, 15%)
Urinary frequency (all grades, 15%)
Urinary tract infection (all grades, 15%)
Cystitis (grade 3-4, 1%)
Dysuria (grade 3-4, 1%)
Hematuria (grade 3-4, 1%)
Urinary frequency (grade 3-4, 1%)
Urinary tract infection (grade 3-4, 1%)
Pharyngitis (all grades, 12%)
Rhinitis (all grades, 10%)
Back pain (all grades, 20%)
Back pain (grade 3-4, 3%)
Arthralgia (all grades, 18%)
Arthralgia (grade 3-4, 1%)
Myalgia (all grades, 8%)
Myalgia (grade 3-4, 1%)
Dyspnea (all grades, 28%)
Dyspnea (grade 3-4, 9%)
Cough (all grades, 26%)
Cough (grade 3-4, 1%)
Epistaxis (all grades, 12%)
Eczema (all grades, 47%)
Exfoliative dermatitis (all grades, 47%)
Maculopapular rash (all grades, 47%)
Pruritic rash (all grades, 47%)
Pustular rash (all grades, 47%)
Rash NOS (all grades, 47%)
Vesiculobullous rash (all grades, 47%)
Epistaxis (grade 3-4, 5%)
Eczema (grade 3-4, 5%)
Exfoliative dermatitis (grade 3-4, 5%)
Maculopapular rash (grade 3-4, 5%)
Pruritic rash (grade 3-4, 5%)
Pustular rash (grade 3-4, 5%)
Rash NOS (grade 3-4, 5%)
Vesiculobullous rash (grade 3-4, 5%)
Pruritus (all grades, 19%)
Pruritus (grade 3-4, 1%)
Nail disorder (all grades, 14%)
Dry skin (all grades, 11%)
Dry skin (grade 3-4, 1%)
Acne (all grades, 10%)
Taste loss (all grades, 20%)
Taste perversion (all grades, 20%)
Insomnia (all grades, 12%)
Insomnia (grade 3-4, 1%)
Depression (all grades, 4%)
Conjunctivitis (7%)
Hypersensitivity reaction (9%)
Pneumonia (8%)
Upper respiratory tract infection (7%)
Healing impaired (1%)
Hypertension (7%)
Venous thromboembolism (2%)
Thrombophlebitis (1%)
Hemoglobin decreased (all grades, 94%)
Hemoglobin decreased (grade 3-4, 20%)
Lymphocyte count decreased (all grades, 53%)
Lymphocyte count decreased (grade 3-4, 16%)
Neutrophil count decreased (all grades, 19%)
Neutrophil count decreased (grade 3-4, 5%)
Platelets decreased (all grades, 40%)
Platelets decreased (grade 3-4, 1%)
Leukocyte count decreased (all grades, 32%)
Leukocyte count decreased (grade 3-4, 1%)
Alkaline phosphatase increased (all grades, 68%)
Alkaline phosphatase increased (grade 3-4, 3%)
AST increased (all grades, 38%)
AST increased (grade 3-4, 2%)
Creatinine increased (all grades, 57%)
Creatinine increased (grade 3-4, 3%)
Glucose increased (all grades, 89%)
Glucose increased (grade 3-4, 16%)
Blood phosphorus decreased (all grades, 49%)
Blood phosphorus decreased (grade 3-4, 18%)
Bilirubin total increased (all grades, 8%)
Bilirubin total increased (grade 3-4, 1%)
Cholesterol total increased (all grades, 87%)
Cholesterol total increased (grade 3-4, 2%)
Triglyceride increased (all grades, 83%)
Triglyceride increased (grade 3-4, 44%)
Potassium decreased (all grades, 21%)
Potassium decreased (grade 3-4, 5%)
Sources:
10 mg/m2 3 times / week multiple, intravenous (starting)
Dose: 10 mg/m2, 3 times / week
Route: intravenous
Route: multiple
Dose: 10 mg/m2, 3 times / week
Sources:
unhealthy, 9 years (range: 1-21 years)
n = 5
Health Status: unhealthy
Condition: acute lymphoblastic leukaemia
Age Group: 9 years (range: 1-21 years)
Sex: M+F
Population Size: 5
Sources:
DLT: Hypertension, Mucositis...
Dose limiting toxicities:
Hypertension (grade 3, 1 patient)
Mucositis (grade 3, 1 patient)
Gamma-glutamyltransferase increased (grade 3, 1 patient)
Hypertriglyceridaemia (grade 4, 1 patient)
Sources:
7.5 mg/m2 2 times / week multiple, intravenous
Dose: 7.5 mg/m2, 2 times / week
Route: intravenous
Route: multiple
Dose: 7.5 mg/m2, 2 times / week
Sources:
unhealthy, 9 years (range: 1-21 years)
n = 5
Health Status: unhealthy
Condition: acute lymphoblastic leukaemia
Age Group: 9 years (range: 1-21 years)
Sex: M+F
Population Size: 5
Sources:
DLT: Hypertriglyceridemia, Gamma-glutamyltransferase increased...
Dose limiting toxicities:
Hypertriglyceridemia (grade 4, 2 patients)
Gamma-glutamyltransferase increased (1 patient)
Alkaline phosphatase increased (1 patient)
Anorexia (grade 2, 1 patient)
Sources:
7.5 mg/m2 3 times / week multiple, intravenous
Dose: 7.5 mg/m2, 3 times / week
Route: intravenous
Route: multiple
Dose: 7.5 mg/m2, 3 times / week
Sources:
unhealthy, 9 years (range: 1-21 years)
n = 6
Health Status: unhealthy
Condition: acute lymphoblastic leukaemia
Age Group: 9 years (range: 1-21 years)
Sex: M+F
Population Size: 6
Sources:
DLT: Sepsis, Mucositis...
Dose limiting toxicities:
Sepsis (grade 5, 1 patient)
Mucositis (grade 5, 1 patient)
Acidosis (grade 5, 1 patient)
Reversible posterior leukoencephalopathy syndrome (1 patient)
Perianal ulcer (grade 2, 1 patient)
Gamma-glutamyltransferase increased (1 patient)
Sources:
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources: Page: p.80
unhealthy
n = 208
Health Status: unhealthy
Population Size: 208
Sources: Page: p.80
Disc. AE: Interstitial lung disease, Asthenia...
AEs leading to
discontinuation/dose reduction:
Interstitial lung disease (grade 5)
Asthenia (3 patients)
Creatinine increased (3 patients)
Anemia (2 patients)
Abdominal pain (2 patients)
Peripheral edema (2 patients)
Cerebrovascular accident (grade 5, 1 patient)
Dyspnea (1 patient)
Lung infiltration (1 patient)
Sources: Page: p.80
AEs

AEs

AESignificanceDosePopulation
Anorexia grade 3, 1 patient
DLT
150 mg/m2 1 times / week multiple, intravenous
Dose: 150 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 150 mg/m2, 1 times / week
Sources:
unhealthy, 11 years (range: 4-21 years)
n = 7
Health Status: unhealthy
Condition: Recurrent/Refractory Solid Tumors
Age Group: 11 years (range: 4-21 years)
Sex: M+F
Population Size: 7
Sources:
Diarrhea grade 1-2, 1 patient
220 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 220 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 220 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 30-63 years)
n = 9
Health Status: unhealthy
Condition: solid tumor refractory
Age Group: 54 years (range: 30-63 years)
Sex: M+F
Population Size: 9
Sources:
Thrombocytopenia grade 1-2, 1 patient
220 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 220 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 220 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 30-63 years)
n = 9
Health Status: unhealthy
Condition: solid tumor refractory
Age Group: 54 years (range: 30-63 years)
Sex: M+F
Population Size: 9
Sources:
Peripheral edema grade 1-2, 2 patients
220 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 220 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 220 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 30-63 years)
n = 9
Health Status: unhealthy
Condition: solid tumor refractory
Age Group: 54 years (range: 30-63 years)
Sex: M+F
Population Size: 9
Sources:
Taste perversion grade 1-2, 2 patients
220 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 220 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 220 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 30-63 years)
n = 9
Health Status: unhealthy
Condition: solid tumor refractory
Age Group: 54 years (range: 30-63 years)
Sex: M+F
Population Size: 9
Sources:
Weight loss grade 1-2, 2 patients
220 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 220 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 220 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 30-63 years)
n = 9
Health Status: unhealthy
Condition: solid tumor refractory
Age Group: 54 years (range: 30-63 years)
Sex: M+F
Population Size: 9
Sources:
Vomiting grade 1-2, 3 patients
220 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 220 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 220 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 30-63 years)
n = 9
Health Status: unhealthy
Condition: solid tumor refractory
Age Group: 54 years (range: 30-63 years)
Sex: M+F
Population Size: 9
Sources:
Nausea grade 1-2, 5 patients
220 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 220 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 220 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 30-63 years)
n = 9
Health Status: unhealthy
Condition: solid tumor refractory
Age Group: 54 years (range: 30-63 years)
Sex: M+F
Population Size: 9
Sources:
Mucositis grade 1-2, 7 patients
220 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 220 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 220 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 30-63 years)
n = 9
Health Status: unhealthy
Condition: solid tumor refractory
Age Group: 54 years (range: 30-63 years)
Sex: M+F
Population Size: 9
Sources:
Asthenia grade 3, 1 patient
DLT
220 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 220 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 220 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 30-63 years)
n = 9
Health Status: unhealthy
Condition: solid tumor refractory
Age Group: 54 years (range: 30-63 years)
Sex: M+F
Population Size: 9
Sources:
Stomatitis grade 3, 1 patient
DLT
220 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 220 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 220 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 30-63 years)
n = 9
Health Status: unhealthy
Condition: solid tumor refractory
Age Group: 54 years (range: 30-63 years)
Sex: M+F
Population Size: 9
Sources:
Hypertriglyceridemia grade 3-4, 1 patient
220 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 220 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 220 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 30-63 years)
n = 9
Health Status: unhealthy
Condition: solid tumor refractory
Age Group: 54 years (range: 30-63 years)
Sex: M+F
Population Size: 9
Sources:
Mucositis grade 3-4, 1 patient
220 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 220 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 220 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 30-63 years)
n = 9
Health Status: unhealthy
Condition: solid tumor refractory
Age Group: 54 years (range: 30-63 years)
Sex: M+F
Population Size: 9
Sources:
Hypercholesterolemia grade 3-4, 2 patients
220 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 220 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 220 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 30-63 years)
n = 9
Health Status: unhealthy
Condition: solid tumor refractory
Age Group: 54 years (range: 30-63 years)
Sex: M+F
Population Size: 9
Sources:
Healing impaired 1%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Thrombophlebitis 1%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Venous thromboembolism 2%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Conjunctivitis 7%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Hypertension 7%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Upper respiratory tract infection 7%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Pneumonia 8%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Hypersensitivity reaction 9%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Acne all grades, 10%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Rhinitis all grades, 10%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Dry skin all grades, 11%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Epistaxis all grades, 12%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Insomnia all grades, 12%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Pharyngitis all grades, 12%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Nail disorder all grades, 14%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Cystitis all grades, 15%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Dysuria all grades, 15%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Headache all grades, 15%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Hematuria all grades, 15%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Urinary frequency all grades, 15%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Urinary tract infection all grades, 15%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Chest pain all grades, 16%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Arthralgia all grades, 18%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Neutrophil count decreased all grades, 19%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Pruritus all grades, 19%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Vomiting all grades, 19%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Weight loss all grades, 19%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Abscess all grades, 20%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Back pain all grades, 20%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Bronchitis all grades, 20%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Cellulitis all grades, 20%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Constipation all grades, 20%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Herpes simplex all grades, 20%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Herpes zoster all grades, 20%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Infection NOS all grades, 20%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Taste loss all grades, 20%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Taste perversion all grades, 20%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Abdominal pain all grades, 21%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Potassium decreased all grades, 21%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Pyrexia all grades, 24%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Cough all grades, 26%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Diarrhea all grades, 27%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Dyspnea all grades, 28%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Pain all grades, 28%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Anorexia all grades, 32%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Leukocyte count decreased all grades, 32%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Edema face all grades, 35%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Edema all grades, 35%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Peripheral edema all grades, 35%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Nausea all grades, 37%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
AST increased all grades, 38%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Depression all grades, 4%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Platelets decreased all grades, 40%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Aphthous stomatitis all grades, 41%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Glossitis all grades, 41%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Mouth ulceration all grades, 41%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Mucositis all grades, 41%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Stomatitis all grades, 41%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Eczema all grades, 47%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Exfoliative dermatitis all grades, 47%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Maculopapular rash all grades, 47%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Pruritic rash all grades, 47%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Pustular rash all grades, 47%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Rash NOS all grades, 47%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Vesiculobullous rash all grades, 47%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Blood phosphorus decreased all grades, 49%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Asthenia all grades, 51%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Lymphocyte count decreased all grades, 53%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Creatinine increased all grades, 57%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Alkaline phosphatase increased all grades, 68%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Bilirubin total increased all grades, 8%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Chills all grades, 8%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Myalgia all grades, 8%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Triglyceride increased all grades, 83%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Cholesterol total increased all grades, 87%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Glucose increased all grades, 89%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Hemoglobin decreased all grades, 94%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Arthralgia grade 3-4, 1%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Bilirubin total increased grade 3-4, 1%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Chest pain grade 3-4, 1%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Chills grade 3-4, 1%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Cough grade 3-4, 1%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Cystitis grade 3-4, 1%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Diarrhea grade 3-4, 1%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Dry skin grade 3-4, 1%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Dysuria grade 3-4, 1%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Headache grade 3-4, 1%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Hematuria grade 3-4, 1%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Insomnia grade 3-4, 1%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Leukocyte count decreased grade 3-4, 1%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Myalgia grade 3-4, 1%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Platelets decreased grade 3-4, 1%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Pruritus grade 3-4, 1%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Pyrexia grade 3-4, 1%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Urinary frequency grade 3-4, 1%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Urinary tract infection grade 3-4, 1%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Weight loss grade 3-4, 1%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Asthenia grade 3-4, 11%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Glucose increased grade 3-4, 16%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Lymphocyte count decreased grade 3-4, 16%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Blood phosphorus decreased grade 3-4, 18%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
AST increased grade 3-4, 2%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Cholesterol total increased grade 3-4, 2%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Nausea grade 3-4, 2%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Vomiting grade 3-4, 2%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Hemoglobin decreased grade 3-4, 20%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Abscess grade 3-4, 3%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Alkaline phosphatase increased grade 3-4, 3%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Anorexia grade 3-4, 3%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Aphthous stomatitis grade 3-4, 3%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Back pain grade 3-4, 3%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Bronchitis grade 3-4, 3%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Cellulitis grade 3-4, 3%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Creatinine increased grade 3-4, 3%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Edema face grade 3-4, 3%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Edema grade 3-4, 3%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Glossitis grade 3-4, 3%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Herpes simplex grade 3-4, 3%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Herpes zoster grade 3-4, 3%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Infection NOS grade 3-4, 3%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Mouth ulceration grade 3-4, 3%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Mucositis grade 3-4, 3%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Peripheral edema grade 3-4, 3%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Stomatitis grade 3-4, 3%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Abdominal pain grade 3-4, 4%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Triglyceride increased grade 3-4, 44%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Eczema grade 3-4, 5%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Epistaxis grade 3-4, 5%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Exfoliative dermatitis grade 3-4, 5%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Maculopapular rash grade 3-4, 5%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Neutrophil count decreased grade 3-4, 5%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Pain grade 3-4, 5%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Potassium decreased grade 3-4, 5%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Pruritic rash grade 3-4, 5%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Pustular rash grade 3-4, 5%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Rash NOS grade 3-4, 5%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Vesiculobullous rash grade 3-4, 5%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Dyspnea grade 3-4, 9%
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources:
unhealthy, 59 years (range 23-86)
n = 208
Health Status: unhealthy
Condition: renal cell carcinoma
Age Group: 59 years (range 23-86)
Sex: M+F
Population Size: 208
Sources:
Gamma-glutamyltransferase increased grade 3, 1 patient
DLT
10 mg/m2 3 times / week multiple, intravenous (starting)
Dose: 10 mg/m2, 3 times / week
Route: intravenous
Route: multiple
Dose: 10 mg/m2, 3 times / week
Sources:
unhealthy, 9 years (range: 1-21 years)
n = 5
Health Status: unhealthy
Condition: acute lymphoblastic leukaemia
Age Group: 9 years (range: 1-21 years)
Sex: M+F
Population Size: 5
Sources:
Hypertension grade 3, 1 patient
DLT
10 mg/m2 3 times / week multiple, intravenous (starting)
Dose: 10 mg/m2, 3 times / week
Route: intravenous
Route: multiple
Dose: 10 mg/m2, 3 times / week
Sources:
unhealthy, 9 years (range: 1-21 years)
n = 5
Health Status: unhealthy
Condition: acute lymphoblastic leukaemia
Age Group: 9 years (range: 1-21 years)
Sex: M+F
Population Size: 5
Sources:
Mucositis grade 3, 1 patient
DLT
10 mg/m2 3 times / week multiple, intravenous (starting)
Dose: 10 mg/m2, 3 times / week
Route: intravenous
Route: multiple
Dose: 10 mg/m2, 3 times / week
Sources:
unhealthy, 9 years (range: 1-21 years)
n = 5
Health Status: unhealthy
Condition: acute lymphoblastic leukaemia
Age Group: 9 years (range: 1-21 years)
Sex: M+F
Population Size: 5
Sources:
Hypertriglyceridaemia grade 4, 1 patient
DLT
10 mg/m2 3 times / week multiple, intravenous (starting)
Dose: 10 mg/m2, 3 times / week
Route: intravenous
Route: multiple
Dose: 10 mg/m2, 3 times / week
Sources:
unhealthy, 9 years (range: 1-21 years)
n = 5
Health Status: unhealthy
Condition: acute lymphoblastic leukaemia
Age Group: 9 years (range: 1-21 years)
Sex: M+F
Population Size: 5
Sources:
Alkaline phosphatase increased 1 patient
DLT
7.5 mg/m2 2 times / week multiple, intravenous
Dose: 7.5 mg/m2, 2 times / week
Route: intravenous
Route: multiple
Dose: 7.5 mg/m2, 2 times / week
Sources:
unhealthy, 9 years (range: 1-21 years)
n = 5
Health Status: unhealthy
Condition: acute lymphoblastic leukaemia
Age Group: 9 years (range: 1-21 years)
Sex: M+F
Population Size: 5
Sources:
Gamma-glutamyltransferase increased 1 patient
DLT
7.5 mg/m2 2 times / week multiple, intravenous
Dose: 7.5 mg/m2, 2 times / week
Route: intravenous
Route: multiple
Dose: 7.5 mg/m2, 2 times / week
Sources:
unhealthy, 9 years (range: 1-21 years)
n = 5
Health Status: unhealthy
Condition: acute lymphoblastic leukaemia
Age Group: 9 years (range: 1-21 years)
Sex: M+F
Population Size: 5
Sources:
Anorexia grade 2, 1 patient
DLT
7.5 mg/m2 2 times / week multiple, intravenous
Dose: 7.5 mg/m2, 2 times / week
Route: intravenous
Route: multiple
Dose: 7.5 mg/m2, 2 times / week
Sources:
unhealthy, 9 years (range: 1-21 years)
n = 5
Health Status: unhealthy
Condition: acute lymphoblastic leukaemia
Age Group: 9 years (range: 1-21 years)
Sex: M+F
Population Size: 5
Sources:
Hypertriglyceridemia grade 4, 2 patients
DLT
7.5 mg/m2 2 times / week multiple, intravenous
Dose: 7.5 mg/m2, 2 times / week
Route: intravenous
Route: multiple
Dose: 7.5 mg/m2, 2 times / week
Sources:
unhealthy, 9 years (range: 1-21 years)
n = 5
Health Status: unhealthy
Condition: acute lymphoblastic leukaemia
Age Group: 9 years (range: 1-21 years)
Sex: M+F
Population Size: 5
Sources:
Gamma-glutamyltransferase increased 1 patient
DLT
7.5 mg/m2 3 times / week multiple, intravenous
Dose: 7.5 mg/m2, 3 times / week
Route: intravenous
Route: multiple
Dose: 7.5 mg/m2, 3 times / week
Sources:
unhealthy, 9 years (range: 1-21 years)
n = 6
Health Status: unhealthy
Condition: acute lymphoblastic leukaemia
Age Group: 9 years (range: 1-21 years)
Sex: M+F
Population Size: 6
Sources:
Reversible posterior leukoencephalopathy syndrome 1 patient
DLT
7.5 mg/m2 3 times / week multiple, intravenous
Dose: 7.5 mg/m2, 3 times / week
Route: intravenous
Route: multiple
Dose: 7.5 mg/m2, 3 times / week
Sources:
unhealthy, 9 years (range: 1-21 years)
n = 6
Health Status: unhealthy
Condition: acute lymphoblastic leukaemia
Age Group: 9 years (range: 1-21 years)
Sex: M+F
Population Size: 6
Sources:
Perianal ulcer grade 2, 1 patient
DLT
7.5 mg/m2 3 times / week multiple, intravenous
Dose: 7.5 mg/m2, 3 times / week
Route: intravenous
Route: multiple
Dose: 7.5 mg/m2, 3 times / week
Sources:
unhealthy, 9 years (range: 1-21 years)
n = 6
Health Status: unhealthy
Condition: acute lymphoblastic leukaemia
Age Group: 9 years (range: 1-21 years)
Sex: M+F
Population Size: 6
Sources:
Acidosis grade 5, 1 patient
DLT
7.5 mg/m2 3 times / week multiple, intravenous
Dose: 7.5 mg/m2, 3 times / week
Route: intravenous
Route: multiple
Dose: 7.5 mg/m2, 3 times / week
Sources:
unhealthy, 9 years (range: 1-21 years)
n = 6
Health Status: unhealthy
Condition: acute lymphoblastic leukaemia
Age Group: 9 years (range: 1-21 years)
Sex: M+F
Population Size: 6
Sources:
Mucositis grade 5, 1 patient
DLT
7.5 mg/m2 3 times / week multiple, intravenous
Dose: 7.5 mg/m2, 3 times / week
Route: intravenous
Route: multiple
Dose: 7.5 mg/m2, 3 times / week
Sources:
unhealthy, 9 years (range: 1-21 years)
n = 6
Health Status: unhealthy
Condition: acute lymphoblastic leukaemia
Age Group: 9 years (range: 1-21 years)
Sex: M+F
Population Size: 6
Sources:
Sepsis grade 5, 1 patient
DLT
7.5 mg/m2 3 times / week multiple, intravenous
Dose: 7.5 mg/m2, 3 times / week
Route: intravenous
Route: multiple
Dose: 7.5 mg/m2, 3 times / week
Sources:
unhealthy, 9 years (range: 1-21 years)
n = 6
Health Status: unhealthy
Condition: acute lymphoblastic leukaemia
Age Group: 9 years (range: 1-21 years)
Sex: M+F
Population Size: 6
Sources:
Dyspnea 1 patient
Disc. AE
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources: Page: p.80
unhealthy
n = 208
Health Status: unhealthy
Population Size: 208
Sources: Page: p.80
Lung infiltration 1 patient
Disc. AE
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources: Page: p.80
unhealthy
n = 208
Health Status: unhealthy
Population Size: 208
Sources: Page: p.80
Abdominal pain 2 patients
Disc. AE
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources: Page: p.80
unhealthy
n = 208
Health Status: unhealthy
Population Size: 208
Sources: Page: p.80
Anemia 2 patients
Disc. AE
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources: Page: p.80
unhealthy
n = 208
Health Status: unhealthy
Population Size: 208
Sources: Page: p.80
Peripheral edema 2 patients
Disc. AE
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources: Page: p.80
unhealthy
n = 208
Health Status: unhealthy
Population Size: 208
Sources: Page: p.80
Asthenia 3 patients
Disc. AE
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources: Page: p.80
unhealthy
n = 208
Health Status: unhealthy
Population Size: 208
Sources: Page: p.80
Creatinine increased 3 patients
Disc. AE
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources: Page: p.80
unhealthy
n = 208
Health Status: unhealthy
Population Size: 208
Sources: Page: p.80
Cerebrovascular accident grade 5, 1 patient
Disc. AE
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources: Page: p.80
unhealthy
n = 208
Health Status: unhealthy
Population Size: 208
Sources: Page: p.80
Interstitial lung disease grade 5
Disc. AE
25 mg 1 times / week steady, intravenous
Recommended
Dose: 25 mg, 1 times / week
Route: intravenous
Route: steady
Dose: 25 mg, 1 times / week
Sources: Page: p.80
unhealthy
n = 208
Health Status: unhealthy
Population Size: 208
Sources: Page: p.80
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no [IC50 27 uM]
no
no
no
no
no
no
yes [IC50 14 uM]
yes [IC50 2.2 uM]
no (co-administration study)
Comment: To investigate the inhibition potential of temsirolimus, a drug-drug interaction study with desipramine (a CYP2D6 substrate) was completed. The statistical analysis concludes that the 90% CI for the LSGM ratios of Cmax, AUCt and AUC of desipramine were within the range of 80-125%.
Page: 7.0
yes [IC50 5.5 uM]
yes
yes
no (co-administration study)
Comment: desipramine concentrations were not effected by co-administration with temsirolimus in-vivo, therefore no inhibition of CYP3A4 of expected.
Page: 7.0
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
yes (co-administration study)
Comment: Drug-drug interaction studies indicate an 56% reduction in sirolimus exposure (AUC), and no effect on temsirolimus exposure when administered with rifampin. Coadministration of IV temsirolimus with ketoconazole did not effect the exposure of temsirolimus but increased the exposure (AUC) of sirolimus by 3.1-fold.
Page: 7.0
no
no
no
no
yes
yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Effect of Targeting Clusterin Using OGX-011 on Antitumor Activity of Temsirolimus in a Human Renal Cell Carcinoma Model.
2017 Feb
Patents

Sample Use Guides

Renal Cell Carcinoma General Dosage IV 25 mg once weekly.
Route of Administration: Intravenous
Temsirolimus (10uM) inhibited the growth of Human Renal Cell Carcinoma Caki-1 growth approx. by 60%
Substance Class Chemical
Created
by admin
on Sat Jun 26 15:11:21 UTC 2021
Edited
by admin
on Sat Jun 26 15:11:21 UTC 2021
Record UNII
624KN6GM2T
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TEMSIROLIMUS
EMA EPAR   INN   JAN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
TEMSIROLIMUS [VANDF]
Common Name English
RAPAMYCIN 42-(2,2-BIS(HYDROXYMETHYL)PROPIONATE)
Common Name English
TORISEL
Brand Name English
TEMSIROLIMUS [JAN]
Common Name English
TEMSIROLIMUS [EMA EPAR]
Common Name English
TEMSIROLIMUS [ORANGE BOOK]
Common Name English
TEMSIROLIMUS [USAN]
Common Name English
TEMSIROLIMUS [WHO-DD]
Common Name English
TEMSIROLIMUS [INN]
Common Name English
RAPAMYCIN, 42-(3-HYDROXY-2-(HYDROXYMETHYL)-2-METHYLPROPANOATE)
Common Name English
CCI-779
Code English
TEMSIROLIMUS [MI]
Common Name English
TEMSIROLIMUS [MART.]
Common Name English
Classification Tree Code System Code
NDF-RT N0000175076
Created by admin on Sat Jun 26 15:11:22 UTC 2021 , Edited by admin on Sat Jun 26 15:11:22 UTC 2021
EMA ASSESSMENT REPORTS TORISEL (AUTHORIZED: LYMPHOMA, MANTLE-CELL)
Created by admin on Sat Jun 26 15:11:22 UTC 2021 , Edited by admin on Sat Jun 26 15:11:22 UTC 2021
EMA ASSESSMENT REPORTS TORISEL (AUTHORIZED: CARCINOMA, RENAL CELL)
Created by admin on Sat Jun 26 15:11:22 UTC 2021 , Edited by admin on Sat Jun 26 15:11:22 UTC 2021
NDF-RT N0000175605
Created by admin on Sat Jun 26 15:11:22 UTC 2021 , Edited by admin on Sat Jun 26 15:11:22 UTC 2021
NCI_THESAURUS C2201
Created by admin on Sat Jun 26 15:11:22 UTC 2021 , Edited by admin on Sat Jun 26 15:11:22 UTC 2021
FDA ORPHAN DRUG 196404
Created by admin on Sat Jun 26 15:11:22 UTC 2021 , Edited by admin on Sat Jun 26 15:11:22 UTC 2021
LIVERTOX 933
Created by admin on Sat Jun 26 15:11:22 UTC 2021 , Edited by admin on Sat Jun 26 15:11:22 UTC 2021
WHO-ATC L01XE09
Created by admin on Sat Jun 26 15:11:22 UTC 2021 , Edited by admin on Sat Jun 26 15:11:22 UTC 2021
WHO-VATC QL01XE09
Created by admin on Sat Jun 26 15:11:22 UTC 2021 , Edited by admin on Sat Jun 26 15:11:22 UTC 2021
EU-Orphan Drug EU/3/06/365
Created by admin on Sat Jun 26 15:11:22 UTC 2021 , Edited by admin on Sat Jun 26 15:11:22 UTC 2021
Code System Code Type Description
EVMPD
SUB21308
Created by admin on Sat Jun 26 15:11:22 UTC 2021 , Edited by admin on Sat Jun 26 15:11:22 UTC 2021
PRIMARY
IUPHAR
5892
Created by admin on Sat Jun 26 15:11:22 UTC 2021 , Edited by admin on Sat Jun 26 15:11:22 UTC 2021
PRIMARY
HSDB
7931
Created by admin on Sat Jun 26 15:11:22 UTC 2021 , Edited by admin on Sat Jun 26 15:11:22 UTC 2021
PRIMARY
DRUG BANK
DB06287
Created by admin on Sat Jun 26 15:11:22 UTC 2021 , Edited by admin on Sat Jun 26 15:11:22 UTC 2021
PRIMARY
DRUG CENTRAL
4161
Created by admin on Sat Jun 26 15:11:22 UTC 2021 , Edited by admin on Sat Jun 26 15:11:22 UTC 2021
PRIMARY
LACTMED
Temsirolimus
Created by admin on Sat Jun 26 15:11:22 UTC 2021 , Edited by admin on Sat Jun 26 15:11:22 UTC 2021
PRIMARY
INN
8212
Created by admin on Sat Jun 26 15:11:22 UTC 2021 , Edited by admin on Sat Jun 26 15:11:22 UTC 2021
PRIMARY
MERCK INDEX
M10555
Created by admin on Sat Jun 26 15:11:22 UTC 2021 , Edited by admin on Sat Jun 26 15:11:22 UTC 2021
PRIMARY Merck Index
FDA UNII
624KN6GM2T
Created by admin on Sat Jun 26 15:11:22 UTC 2021 , Edited by admin on Sat Jun 26 15:11:22 UTC 2021
PRIMARY
MESH
C401859
Created by admin on Sat Jun 26 15:11:22 UTC 2021 , Edited by admin on Sat Jun 26 15:11:22 UTC 2021
PRIMARY
PUBCHEM
6918289
Created by admin on Sat Jun 26 15:11:22 UTC 2021 , Edited by admin on Sat Jun 26 15:11:22 UTC 2021
PRIMARY
WIKIPEDIA
Temsirolimus
Created by admin on Sat Jun 26 15:11:22 UTC 2021 , Edited by admin on Sat Jun 26 15:11:22 UTC 2021
PRIMARY
ChEMBL
CHEMBL1201182
Created by admin on Sat Jun 26 15:11:22 UTC 2021 , Edited by admin on Sat Jun 26 15:11:22 UTC 2021
PRIMARY
CAS
162635-04-3
Created by admin on Sat Jun 26 15:11:22 UTC 2021 , Edited by admin on Sat Jun 26 15:11:22 UTC 2021
PRIMARY
EPA CompTox
162635-04-3
Created by admin on Sat Jun 26 15:11:22 UTC 2021 , Edited by admin on Sat Jun 26 15:11:22 UTC 2021
PRIMARY
NCI_THESAURUS
C1844
Created by admin on Sat Jun 26 15:11:22 UTC 2021 , Edited by admin on Sat Jun 26 15:11:22 UTC 2021
PRIMARY
RXCUI
657797
Created by admin on Sat Jun 26 15:11:22 UTC 2021 , Edited by admin on Sat Jun 26 15:11:22 UTC 2021
PRIMARY RxNorm
Related Record Type Details
METABOLIC ENZYME -> INHIBITOR
IC50
METABOLIC ENZYME -> INHIBITOR
IC50
METABOLIC ENZYME -> INHIBITOR
IC50
BINDER->LIGAND
The percentage of [14C]temsirolimus bound to proteins at concentrations of 100 ng/mL when calculated for undiluted human plasma in erythrocyte suspensions was 87.1%.
BINDING
METABOLIC ENZYME -> INHIBITOR
IC50
METABOLIC ENZYME -> SUBSTRATE
MAJOR
TARGET -> INHIBITOR
BINDER->LIGAND
The percentage of [14C]temsirolimus bound to proteins at concentrations of 10 ng/mL when calculated for undiluted human plasma in erythrocyte suspensions was 85.0%
BINDING
Related Record Type Details
METABOLITE -> PARENT
METABOLITE -> PARENT
METABOLITE -> PARENT
METABOLITE -> PARENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC INTRAVENOUS ADMINISTRATION

SINGLE DOSE